Nature Communications (Dec 2022)
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
- Nerea Berastegui,
- Marina Ainciburu,
- Juan P. Romero,
- Paula Garcia-Olloqui,
- Ana Alfonso-Pierola,
- Céline Philippe,
- Amaia Vilas-Zornoza,
- Patxi San Martin-Uriz,
- Raquel Ruiz-Hernández,
- Ander Abarrategi,
- Raquel Ordoñez,
- Diego Alignani,
- Sarai Sarvide,
- Laura Castro-Labrador,
- José M. Lamo-Espinosa,
- Mikel San-Julian,
- Tamara Jimenez,
- Félix López-Cadenas,
- Sandra Muntion,
- Fermin Sanchez-Guijo,
- Antonieta Molero,
- Maria Julia Montoro,
- Bárbara Tazón,
- Guillermo Serrano,
- Aintzane Diaz-Mazkiaran,
- Mikel Hernaez,
- Sofía Huerga,
- Findlay Bewicke-Copley,
- Ana Rio-Machin,
- Matthew T. Maurano,
- María Díez-Campelo,
- David Valcarcel,
- Kevin Rouault-Pierre,
- David Lara-Astiaso,
- Teresa Ezponda,
- Felipe Prosper
Affiliations
- Nerea Berastegui
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Marina Ainciburu
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Juan P. Romero
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Paula Garcia-Olloqui
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Ana Alfonso-Pierola
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III
- Céline Philippe
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- Amaia Vilas-Zornoza
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Patxi San Martin-Uriz
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Raquel Ruiz-Hernández
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA)
- Ander Abarrategi
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA)
- Raquel Ordoñez
- Institute for Systems Genetics, NYU School of Medicine
- Diego Alignani
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Sarai Sarvide
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Laura Castro-Labrador
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- José M. Lamo-Espinosa
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN
- Mikel San-Julian
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN
- Tamara Jimenez
- Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca
- Félix López-Cadenas
- Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca
- Sandra Muntion
- Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca
- Fermin Sanchez-Guijo
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III
- Antonieta Molero
- Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Maria Julia Montoro
- Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Bárbara Tazón
- Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Guillermo Serrano
- Computational Biology Program, Institute for data science and artificial intelligence (datai), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Aintzane Diaz-Mazkiaran
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Mikel Hernaez
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III
- Sofía Huerga
- Department of Hematology, Clínica Universidad de Navarra, Universidad de Navarra and CCUN
- Findlay Bewicke-Copley
- Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Ana Rio-Machin
- Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Matthew T. Maurano
- Institute for Systems Genetics, NYU School of Medicine
- María Díez-Campelo
- Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III
- David Valcarcel
- Department of Hematology, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Kevin Rouault-Pierre
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
- David Lara-Astiaso
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Teresa Ezponda
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- Felipe Prosper
- Department of Hematology-Oncology, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA)
- DOI
- https://doi.org/10.1038/s41467-022-35192-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Myelodysplastic syndromes (MDS) are age-related pathologies in which alterations of hematopoietic stem cells lead to abnormal formation of blood cells. Here, the authors study the lesions that these cells undergo in aging and disease, characterizing a factor whose alteration in MDS leads to abnormal blood cell production.
